Document Type : Review Article
Build Goal Health, Inc Ceo & Founder, Los Angles, California, United States
A number of animal disease models have been created in the past to investigate the molecular basis of neurological diseases and identify novel treatments, but their effectiveness has been limited by the absence of comparable animal models. There are still several important problems that need to be overcome, including the high expenses associated with creating animal models, ethical issues, and a lack of similarity to human disease. More than 90% of medications fail in the last stage of the human clinical trial as a result of inadequate early screening and assessment of the molecules. A novel strategy based on induced pluripotent stem cells has been developed to get around these restrictions (iPSCs). A new road map for clinical translational research and regeneration treatment has been made possible by the discovery of iPSCs. In this paper, we investigate the potential use of patient-derived iPSCs to neurological disorders as well as their significance in scientific and clinical studies for the creation of disease models and a road map for the next of medicine. The role of human iPSCs in the most prevalent neurodegenerative illnesses (such as Parkinson’s and Alzheimer’s disease, diabetic neuropathy) was evaluated. The patient-on-a-chip idea, where iPSCs may be cultivated on 3D matrices within microfluidic devices to produce an in vitro disease model for tailored medication, is another new development in the field of personalized medicine that we looked into.